PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

63.46 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal ↗

August 16, 2026

PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to...

Via MarketBeat

Topics Bankruptcy

PTC Therapeutics Q2 Earnings Call Highlights ↗

July 31, 2026

PTC Therapeutics (NASDAQ:PTCT) reported second-quarter total revenue of $361 million and raised its 2026 outlook, citing continued growth from its Sephience launch and greater durability than expected...

Via MarketBeat

Topics Earnings

PTC Therapeutics (NASDAQ:PTCT) Soars on Q2 Earnings Beat and Raised Guidance ↗

July 30, 2026

Via Chartmill

Topics Earnings

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million ↗

July 13, 2026

This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities.

Via The Motley Fool

Topics Regulatory Compliance

PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup ↗

June 12, 2026

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Delivers Q1 Earnings Beat and Raises 2026 Guidance ↗

May 07, 2026

Via Chartmill

Topics Earnings

PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗

February 19, 2026

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗

February 12, 2026

Via Chartmill

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗

May 29, 2026

This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

PTC Therapeutics Q1 Earnings Call Highlights ↗

May 08, 2026

PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or...

Via MarketBeat

Topics Earnings

PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗

February 07, 2026

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗

February 02, 2026

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗

January 12, 2026

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗

January 09, 2026

Via Chartmill

PTCT Q1 2026 Earnings Transcript ↗

May 08, 2026

PTCT Q1 2026 Earnings Transcript

Via The Motley Fool

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗

January 01, 2026

Via Chartmill

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗

December 15, 2025

PTC Therapeutics stock shows strong earnings momentum and a top-rated technical setup, offering a potential breakout opportunity for growth investors.

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗

December 13, 2025

PTC Therapeutics (PTCT) exemplifies a strong growth stock with a bullish technical setup, combining high sales growth, robust margins, and a potential chart breakout.

Via Chartmill

PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗

December 10, 2025

PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations.

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.